New drug LY4268989 tested in healthy people for safety and absorption
NCT ID NCT06964776
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 38 times
Summary
This completed Phase 1 study tested the drug LY4268989 (MORF-057) in 144 healthy volunteers, including Japanese and Chinese participants. The goal was to measure how the body absorbs and processes the drug, its safety, and how food or other drugs like midazolam affect it. No treatment benefit was expected, as this was an early safety and dosing study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CenExel ACT
Anaheim, California, 92801, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY4268989 (MORF-057)
What this could lead to
If successful, this study could help determine safe dosing and how the drug interacts with other medications, paving the way for future trials in patients.
What could go wrong
This is an early Phase 1 study in healthy people, so it does not test whether the drug works for any disease. Side effects may still emerge, and results may not apply to patients.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.